<table id="table5" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 5: Drug Interactions: Pharmacokinetic Parameters for Etravirine in the Presence of Co-administered Drugs</caption>
<col align="left" valign="top" width="17%"></col>
<col align="center" valign="top" width="17%"></col>
<col align="center" valign="top" width="13%"></col>
<col align="center" valign="top" width="20%"></col>
<col align="center" valign="top" width="11%"></col>
<col align="center" valign="top" width="11%"></col>
<col align="center" valign="top" width="11%"></col>
<thead>
<tr stylecode="Botrule">
<th rowspan="2" stylecode="Lrule Rrule" valign="bottom">Co-administered Drug</th>
<th rowspan="2" stylecode="Rrule" valign="bottom">Dose/Schedule of Co-administered Drug</th>
<th rowspan="2" stylecode="Rrule" valign="bottom">N</th>
<th rowspan="2" stylecode="Rrule" valign="bottom">Exposure</th>
<th colspan="3" stylecode="Rrule" valign="bottom">Mean Ratio of <content stylecode="underline">Etravirine</content>
<br/>Pharmacokinetic Parameters<br/>90% CI; No Effect = 1.00</th>
</tr>
<tr>
<th align="center" stylecode="Rrule botrule" valign="bottom">C<sub>max</sub>
</th>
<th stylecode="Rrule botrule" valign="bottom">AUC</th>
<th stylecode="Rrule botrule" valign="bottom">C<sub>min</sub>
</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="7">CI = Confidence Interval; N = number of subjects with data; N.A. = not available; ↑ = increase; ↓ = decrease; ↔ = no change; q.d. = once daily; b.i.d. = twice daily; q.a.m. = once daily in the morning</td>
</tr>
</tfoot>
<tbody>
<tr stylecode="Botrule">
<td colspan="7" stylecode="Lrule Rrule">
<content stylecode="bold">Co-Administration With Protease Inhibitors (PIs)</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Atazanavir</td>
<td stylecode="Rrule">400 mg q.d.</td>
<td stylecode="Rrule">14</td>
<td stylecode="Rrule">↑</td>
<td stylecode="Rrule">1.47<br/> (1.36-1.59)</td>
<td stylecode="Rrule">1.50<br/> (1.41-1.59)</td>
<td stylecode="Rrule">1.58<br/> (1.46-1.70)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Atazanavir/<br/> ritonavir<footnote id="t5ft1">The expected increase in systemic exposure of etravirine when co-administered with atazanavir/ritonavir (~100%) as outlined in Table 3 is theoretical and based on comparing exposures of etravirine in a drug-drug interaction study with exposure in the pivotal Phase 3 trials (in which darunavir/ritonavir was part of the background regimen).</footnote>
</td>
<td stylecode="Rrule">300/100 mg q.d.</td>
<td stylecode="Rrule">14</td>
<td stylecode="Rrule">↑</td>
<td stylecode="Rrule">1.30<br/> (1.17-1.44)</td>
<td stylecode="Rrule">1.30<br/> (1.18-1.44)</td>
<td stylecode="Rrule">1.26<br/> (1.12-1.42)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Darunavir/<br/> ritonavir</td>
<td stylecode="Rrule">600/100 mg b.i.d.</td>
<td stylecode="Rrule">14</td>
<td stylecode="Rrule">↓</td>
<td stylecode="Rrule">0.68<br/> (0.57-0.82)</td>
<td stylecode="Rrule">0.63<br/> (0.54-0.73)</td>
<td stylecode="Rrule">0.51<br/> (0.44-0.61)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Lopinavir/<br/> ritonavir<br/>(tablet)</td>
<td stylecode="Rrule">400/100 mg b.i.d.</td>
<td stylecode="Rrule">16</td>
<td stylecode="Rrule">↓</td>
<td stylecode="Rrule">0.70<br/>(0.64-0.78)</td>
<td stylecode="Rrule">0.65<br/>(0.59-0.71)</td>
<td stylecode="Rrule">0.55<br/>(0.49-0.62)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Ritonavir</td>
<td stylecode="Rrule">600 mg b.i.d.</td>
<td stylecode="Rrule">11</td>
<td stylecode="Rrule">↓</td>
<td stylecode="Rrule">0.68<br/> (0.55-0.85)</td>
<td stylecode="Rrule">0.54<br/> (0.41-0.73)</td>
<td stylecode="Rrule">N.A.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Saquinavir/<br/> ritonavir<br/>
</td>
<td stylecode="Rrule">1000/100 mg b.i.d.</td>
<td stylecode="Rrule">14</td>
<td stylecode="Rrule">↓</td>
<td stylecode="Rrule">0.63<br/> (0.53-0.75)</td>
<td stylecode="Rrule">0.67<br/> (0.56-0.80)</td>
<td stylecode="Rrule">0.71<br/> (0.58-0.87)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Tipranavir/<br/> ritonavir</td>
<td stylecode="Rrule">500/200 mg b.i.d.</td>
<td stylecode="Rrule">19</td>
<td stylecode="Rrule">↓</td>
<td stylecode="Rrule">0.29<br/> (0.22-0.40)</td>
<td stylecode="Rrule">0.24<br/> (0.18-0.33)</td>
<td stylecode="Rrule">0.18<br/> (0.13-0.25)</td>
</tr>
<tr stylecode="Botrule">
<td colspan="7" stylecode="Lrule Rrule">
<content stylecode="bold">Co-Administration With Nucleoside Reverse Transcriptase Inhibitors (NRTIs)</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Didanosine</td>
<td stylecode="Rrule">400 mg q.d.</td>
<td stylecode="Rrule">15</td>
<td stylecode="Rrule">↔</td>
<td stylecode="Rrule">1.16<br/> (1.02-1.32)</td>
<td stylecode="Rrule">1.11<br/> (0.99-1.25)</td>
<td stylecode="Rrule">1.05<br/> (0.93-1.18)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Tenofovir disoproxil fumarate</td>
<td stylecode="Rrule">300 mg q.d.</td>
<td stylecode="Rrule">23</td>
<td stylecode="Rrule">↓</td>
<td stylecode="Rrule">0.81<br/> (0.75-0.88)</td>
<td stylecode="Rrule">0.81<br/> (0.75-0.88)</td>
<td stylecode="Rrule">0.82<br/> (0.73-0.91)</td>
</tr>
<tr stylecode="Botrule">
<td colspan="7" stylecode="Lrule Rrule">
<content stylecode="bold">Co-Administration With CCR5 Antagonists</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Maraviroc</td>
<td stylecode="Rrule">300 mg b.i.d.</td>
<td stylecode="Rrule">14</td>
<td stylecode="Rrule">↔</td>
<td stylecode="Rrule">1.05<br/>(0.95-1.17)</td>
<td stylecode="Rrule">1.06<br/>(0.99-1.14)</td>
<td stylecode="Rrule">1.08<br/>(0.98-1.19)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Maraviroc (when co-administered with darunavir/ritonavir)<footnote>The reference for etravirine exposure is the pharmacokinetic parameters of etravirine in the presence of darunavir/ritonavir.</footnote>
</td>
<td stylecode="Rrule">150/600/100 mg b.i.d.</td>
<td stylecode="Rrule">10</td>
<td stylecode="Rrule">↔</td>
<td stylecode="Rrule">1.08<br/>(0.98–1.20)</td>
<td stylecode="Rrule">1.00<br/>(0.86–1.15)</td>
<td stylecode="Rrule">0.81<br/>(0.65–1.01)</td>
</tr>
<tr stylecode="Botrule">
<td colspan="7" stylecode="Lrule Rrule">
<content stylecode="bold">Co-Administration With Integrase Strand Transfer Inhibitors</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Raltegravir</td>
<td stylecode="Rrule">400 mg b.i.d.</td>
<td stylecode="Rrule">19</td>
<td stylecode="Rrule">↔</td>
<td stylecode="Rrule">1.04<br/> (0.97-1.12)</td>
<td stylecode="Rrule">1.10<br/> (1.03-1.16)</td>
<td stylecode="Rrule">1.17<br/> (1.10-1.26)</td>
</tr>
<tr stylecode="Botrule">
<td colspan="7" stylecode="Lrule Rrule">
<content stylecode="bold">Co-Administration With Other Drugs</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Atorvastatin</td>
<td stylecode="Rrule">40 mg q.d.</td>
<td stylecode="Rrule">16</td>
<td stylecode="Rrule">↔</td>
<td stylecode="Rrule">0.97<br/> (0.93-1.02)</td>
<td stylecode="Rrule">1.02<br/> (0.97-1.07)</td>
<td stylecode="Rrule">1.10<br/> (1.02-1.19)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Clarithromycin</td>
<td stylecode="Rrule">500 mg b.i.d.</td>
<td stylecode="Rrule">15</td>
<td stylecode="Rrule">↑</td>
<td stylecode="Rrule">1.46<br/> (1.38-1.56)</td>
<td stylecode="Rrule">1.42<br/> (1.34-1.50)</td>
<td stylecode="Rrule">1.46<br/> (1.36-1.58)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Fluconazole</td>
<td stylecode="Rrule">200 mg q.a.m.</td>
<td stylecode="Rrule">16</td>
<td stylecode="Rrule">↑</td>
<td stylecode="Rrule">1.75<br/>(1.60-1.91)</td>
<td stylecode="Rrule">1.86<br/>(1.73-2.00)</td>
<td stylecode="Rrule">2.09<br/>(1.90-2.31)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Omeprazole</td>
<td stylecode="Rrule">40 mg q.d.</td>
<td stylecode="Rrule">18</td>
<td stylecode="Rrule">↑</td>
<td stylecode="Rrule">1.17<br/> (0.96-1.43)</td>
<td stylecode="Rrule">1.41<br/> (1.22-1.62)</td>
<td stylecode="Rrule">N.A.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Paroxetine</td>
<td stylecode="Rrule">20 mg q.d.</td>
<td stylecode="Rrule">16</td>
<td stylecode="Rrule">↔</td>
<td stylecode="Rrule">1.05<br/> (0.96-1.15)</td>
<td stylecode="Rrule">1.01<br/> (0.93-1.10)</td>
<td stylecode="Rrule">1.07<br/> (0.98-1.17)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Ranitidine</td>
<td stylecode="Rrule">150 mg b.i.d.</td>
<td stylecode="Rrule">18</td>
<td stylecode="Rrule">↓</td>
<td stylecode="Rrule">0.94<br/> (0.75-1.17)</td>
<td stylecode="Rrule">0.86<br/> (0.76-0.97)</td>
<td stylecode="Rrule">N.A.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Rifabutin</td>
<td stylecode="Rrule">300 mg q.d.</td>
<td stylecode="Rrule">12</td>
<td stylecode="Rrule">↓</td>
<td stylecode="Rrule">0.63<br/> (0.53-0.74)</td>
<td stylecode="Rrule">0.63<br/> (0.54-0.74)</td>
<td stylecode="Rrule">0.65<br/> (0.56-0.74)</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Voriconazole</td>
<td stylecode="Rrule">200 mg b.i.d.</td>
<td stylecode="Rrule">16</td>
<td stylecode="Rrule">↑</td>
<td stylecode="Rrule">1.26<br/>(1.16-1.38)</td>
<td stylecode="Rrule">1.36<br/>(1.25-1.47)</td>
<td stylecode="Rrule">1.52<br/>(1.41-1.64)</td>
</tr>
</tbody>
</table>